Tickers Trending: Solar Capital (NASDAQ:SLRC), Fortinet Inc. (NASDAQ:FTNT), Columbia Sportswear Company (NASDAQ:COLM), Agenus Inc. (NASDAQ:AGEN), Cummins Inc. (NYSE:CMI)


Solar Capital Ltd. (NASDAQ:SLRC) shares decreased -0.31% in last trading session and ended the day at $16.17. SLRC Gross Margin is 62.10% and its has a return on assets of 2.00%. Solar Capital Ltd. (NASDAQ:SLRC) quarterly performance is -6.00%.

Solar Capital Ltd. (NASDAQ: SLRC) announced that it will release its financial results for the quarter and fiscal year ended December 31, 2015 on Wednesday, February 24, 2016, after the close of the financial markets.

Fortinet Inc. (NASDAQ:FTNT) ended the last trading day at $26.72. Company weekly volatility is calculated as 5.49% and price to cash ratio as 5.04. Fortinet Inc. (NASDAQ:FTNT) showed a weekly performance of 1.37%.

On 28 January, Fortinet Inc. (NASDAQ:FTNT) reported a fourth-quarter loss of $2.5 million, after reporting a profit in the same period a year earlier. The Sunnyvale, California-based company said it had a loss of 1 cent per share. Earnings, adjusted for stock option expense and amortization costs, came to 18 cents per share. The results met Wall Street expectations. The average estimate of 16 analysts surveyed by Zacks Investment Research was also for earnings of 18 cents per share.

On 04 February, Columbia Sportswear Company (NASDAQ:COLM) shares decreased -2.66% and was closed at $52.30. COLM EPS growth in last 5 year was 14.40%. Columbia Sportswear Company (NASDAQ:COLM) year to date (YTD) performance is 7.26%.

Columbia Sportswear Company (NASDAQ: COLM) plans to release financial results of its fourth quarter and full year 2015 at approximately 4:00 p.m. ET on Thursday, February 11, 2016.

Agenus Inc. (NASDAQ:AGEN) shares increased 3.04% in last trading session and ended the day at $3.05. AGEN has a return on assets of -64.20%. Agenus Inc. (NASDAQ:AGEN) quarterly performance is -36.06%.

On 21st January, Agenus Inc. (NASDAQ:AGEN), announced that the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug (IND) application for AGEN1884, an immune checkpoint modulator (CPM) antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4). Clearance was also received for a second CPM antibody partnered with Incyte (INCY) for INCAGN1876, which targets glucocorticoid-induced TNFR-related protein (GITR). Clinical trials for both candidates are expected to begin in the first half of 2016.

Cummins Inc. (NYSE:CMI) caters to the Industrial Goods space. It has a net profit margin of 8.70% and weekly performance is 12.21%. On the last day of trading company shares ended up at $97.57. Cummins Inc. (NYSE:CMI) distance from 50-day simple moving average (SMA50) is 9.17%.

Cummins Inc. (NYSE:CMI) on Thursday reported fourth-quarter earnings of $161 million. On a per-share basis, the Columbus, Indiana-based company said it had net income of 92 cents. Earnings, adjusted for one-time gains and costs, were $2.09 per share. The results topped Wall Street expectations. The average estimate of 14 analysts surveyed by Zacks Investment Research was for earnings of $2.08 per share. The engine maker posted revenue of $4.77 billion in the period, also exceeding Street forecasts. Seven analysts surveyed by Zacks expected $4.71 billion.


Leave a Reply

Your email address will not be published. Required fields are marked *